KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Non-cash Items (2016 - 2025)

Fulgent Genetics' Non-cash Items history spans 9 years, with the latest figure at $134000.0 for Q4 2024.

  • For Q4 2024, Non-cash Items fell 97.27% year-over-year to $134000.0; the TTM value through Dec 2024 reached $134000.0, down 97.27%, while the annual FY2024 figure was $134000.0, 97.27% down from the prior year.
  • Non-cash Items for Q4 2024 was $134000.0 at Fulgent Genetics, down from $4.9 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $21.0 million in Q4 2021 and bottomed at $134000.0 in Q4 2024.
  • The 5-year median for Non-cash Items is $5.4 million (2022), against an average of $9.2 million.
  • The largest annual shift saw Non-cash Items skyrocketed 265.76% in 2020 before it crashed 97.27% in 2024.
  • A 5-year view of Non-cash Items shows it stood at $14.5 million in 2020, then soared by 44.75% to $21.0 million in 2021, then tumbled by 74.15% to $5.4 million in 2022, then decreased by 9.48% to $4.9 million in 2023, then plummeted by 97.27% to $134000.0 in 2024.
  • Per Business Quant, the three most recent readings for FLGT's Non-cash Items are $134000.0 (Q4 2024), $4.9 million (Q4 2023), and $5.4 million (Q4 2022).